Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
🇹🇭 TH Market
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Pharmaceuticals & Biotech
Any
Automobiles
Banks
Capital Goods
Commercial Services
Consumer Durables
Consumer Services
Diversified Financials
Energy
Consumer Retailing
Food, Beverage & Tobacco
Healthcare
Household
Insurance
Materials
Media
Pharmaceuticals & Biotech
Real Estate
Retail
Semiconductors
Software
Tech
Telecom
Transportation
Utilities
Create a narrative
Community
/
Thailand
/
Pharmaceuticals & Biotech
Pharmaceuticals & Biotech Thai Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Pharmaceuticals & Biotech Thai Investing Ideas
All companies
Popular
Undervalued
Overvalued
Mega Lifesciences
AN
AnalystHighTarget
Community Contributor
Aging Populations And Emerging Markets Will Drive Wellness Demand
Key Takeaways Accelerated manufacturing expansion, robust product pipeline, and localization strategies position Mega Lifesciences for outperformance in topline growth and margin resilience. Early focus on prevention-oriented brands and proactive market adaptation may lead to dominant status and sustained earnings growth amid evolving health trends.
View narrative
฿39
FV
21.2% undervalued
intrinsic discount
6.83%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
18 days ago
author updated this narrative
Mega Lifesciences
AN
AnalystConsensusTarget
Based on Analyst Price Targets
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Key Takeaways Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth. Diversified product pipeline and focus on preventive healthcare align with rising demand, driving consistent earnings momentum and unlocking higher value per unit.
View narrative
฿32.14
FV
4.3% undervalued
intrinsic discount
3.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
24 days ago
author updated this narrative
Mega Lifesciences
AN
AnalystLowTarget
Community Contributor
Myanmar Scrutiny And FX Risks Will Dampen Prospects With Upside
Key Takeaways Reliance on traditional products and lack of innovation risk shrinking market relevance and long-term growth opportunities amid evolving consumer preferences. Regulatory, geopolitical, and competitive pressures are likely to drive up costs, increase earnings volatility, and compress margins, challenging overall profitability.
View narrative
฿26
FV
18.3% overvalued
intrinsic discount
0.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 1 month ago
author updated this narrative